China, Sept. 22 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600133039
Registration Time: 2026/09/21
Type: Interventional study
Primary Sponsor: The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=343759
Published by HT Digital Content Services with permission from Health Daily Digest....